Parker-Hannifin Equity Method Investments decreased by 4.8% to $280.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 4.8%, from $294.00M to $280.00M. Over 4 years (FY 2021 to FY 2025), Equity Method Investments shows relatively stable performance with a -1.1% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q2 '21 | Q2 '22 | Q2 '23 | Q2 '24 | Q2 '25 | |
|---|---|---|---|---|---|
| Value | $292.22M | $314.00M | $297.00M | $294.00M | $280.00M |
| QoQ Change | — | +7.5% | -5.4% | -1.0% | -4.8% |
| YoY Change | — | +7.5% | -5.4% | -1.0% | -4.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.